HRAS and cancer: Overall, samples with mutant EGFR/KRAS/HRAS/NRAS/BRAF tended to have increased sensitivity to the corresponding kinase inhibitors in most cancer types, although some of the association did not reach significance (e.g., EGFR with erlotinib in LUAD, P = 0.16 by A-model and P = 0.046 by S-model).